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What is known on this topic? What this paper adds? 
• Patients with lung cancer are at 
increased risk of developing venous 
thromboembolism (VTE), significantly 
affecting morbidity and mortality. 
• Fractal dimension of blood clots is 
significantly higher in patients with lung 
cancer compared to healthy controls, 
suggesting an abnormal clot structure.  
• There are currently no reliable markers 
which accurately quantify pathological clot 
structure. 
• Patients with extensive (stage III & IV) 
lung cancer had significantly higher df as 
compared to those with limited disease 
(stages I & II). 
• Fractal dimension (df) is a new 
technique previously demonstrated to 
quantify clot microstructure, shown to be 
associated with changes observed by 
scanning electron microscopy (SEM).    
• Changes in df were associated with 
similar changes in SEM images, reaffirming 
the link between incipient and mature clot 
structure.   
 
Abstract 
Background: Venous thromboembolism (VTE) is common in cancer patients, and is the second 
commonest cause of death associated with the disease. Patients with chronic inflammation, such 
as cancer, have been shown to have pathological clot structures with modulated mechanical 
properties. Fractal dimension (df) is a new technique which has been shown to act as a marker of 
the microstructure and mechanical properties of blood clots, and can be performed more readily 
than current methods such as scanning electron microscopy (SEM).  
Methods: This study compares df in 87 patients with newly diagnosed lung cancer to 47 matched-
controls, in addition to analysis based on stage of disease. Results were compared with 
conventional markers of coagulation, fibrinolysis and SEM images. 
Results: Significantly increased df was observed in lung cancer patients compared with controls. 
Significantly increased df was observed in patients with extensive (stage 3/4) compared with 
limited disease (stage 1/2) (p<0.05), whilst conventional markers failed to distinguish between 
these groups. The relationship between df of the incipient clot and mature clot microstructure was 
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confirmed by SEM and computational modelling: higher df was associated with highly dense clots 
formed of smaller fibrin fibres in lung cancer patients compared to controls.  
Conclusion: This study demonstrates that df is a sensitive technique which quantifies the structure 
and mechanical properties of blood clots in lung cancer patients, which appears to be modulated 
by stage of disease. This data suggests a potential role in identifying and managing patients with a 
high df, and therefore abnormal clot structure.  
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Introduction 
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary 
embolus (PE) is a common phenomenon affecting 6.5 million people worldwide annually (1,2). 
The incidence is higher in people with cancer who account for 18% of all cases of VTE (3), with 
an estimated 4 to 20% of cancer patients developing VTE during the course of their disease (4). 
VTE contributes significantly to morbidity and mortality in patients with cancer, in whom it 
remains the second commonest cause of death (5). Risk factors for VTE include advancing age, 
metastatic burden, surgery and chemotherapy (3). Cancers are also known to vary in 
thrombogenicity with histological type and primary tumour site. Compared with the general 
population, lung cancer confers a 22-fold increased risk of VTE, second only to haematological 
malignancies (6). 
 
Despite the well-documented incidence of VTE in patients with cancer, little is known on the 
effects of differences in global coagulation on the structure of clots formed, and if these are 
pathologically abnormal compared to healthy individuals. Factors that increase the 
thrombogenicity in malignancy result from release of tumour procoagulants such as tissue factor 
(TF), microparticles and factor VIII (7-10). In addition, chronic inflammation has long been 
associated with cancer (11-13), having an important role in modulating the tumour 
microenvironment and its impact on systemic processes, including proliferation and migration 
(12). It has also been suggested that as cancers metastasize and grow, inflammatory processes 
may be increased (13), which may have greater impact on systemic processes such as 
haemostasis. Previous studies on patients with inflammatory disorders and vascular disease have 
demonstrated the development of pathological clots of a dense, highly polymerised and less 
porous microstructure (14), which may alter mechanical properties of the clot (15-18).  Further 
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studies have suggested that fibrinolytic properties may also be reduced in blood clots in with 
abnormal structure (19,20). It is therefore likely that patients with cancer also form pathological 
clots with similar arrangement and resulting structural properties, which may be modulated by 
stage of disease and accompanying chronic inflammation. There is however, currently no method 
of investigating or quantifying the link between chronic inflammation and its global effect on 
processes such as haemostasis.  
 
Attempts have been undertaken using viscoelastic techniques to investigate clot formation in 
patients with cancer. Several studies using thromboelastography (TEG) and rotational 
thromboelastometry (ROTEM) have suggested its use in predicting thromboembolic 
complications in cancer patients, (21-23) whilst others have demonstrated no differences (24,25). 
However, conflicting results on whether these techniques can be used to accurately assess changes 
in global coagulation in patients with cancer and the relatively small populations of patients with 
mixed primary tumour sites, limit their clinical utility. A larger study of ROTEM parameters 
demonstrated that patients with lung cancer had decreased clotting time and increased maximum 
clot firmness than healthy controls (26). These parameters were further altered in patients with 
extensive lung cancer compared to those with limited disease and in patients who went on to 
develop VTE, but cannot be used to identify differences in coagulation depending on stage of 
disease (26). In combination, these studies suggest that not only do patients with cancer form clots 
faster, but that physical clot properties may also be different in these patients, leading to 
pathological clot formation.         
Recent advances in our understanding of viscoelastic changes in coagulation have resulted in the 
development of multi-faceted biomarker of clot characteristics, including clot microstructure, 
measured by fractal dimension (df), clot formation time (TGP) and viscoelastic clot strength (G`GP) 
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which are all calculated from the gel point (GP) (27-30). In contrast to standard coagulation 
assays, this technique uses unadulterated whole blood and is measured immediately at the bedside 
during real-time formation of the clot. In addition, structure of the early clot, as quantified by df, 
has been established as providing a template for the mature clot when analysed based on 
viscoelastic and imaging data (31,32). We have previously shown that df quantified the 
microstructure of the incipient clot in normal and anticoagulated blood in a sensitive and highly 
reproducible manner (30,32), and that this is important in quantifying the underlying pathological 
effect on clot structure (33). Similarly, increased df, has been demonstrated in patients with 
inflammatory vascular disorders (34,35), correlating with scanning electron microscopy (SEM) 
images of the mature blood clot. Measurement of global coagulation and resulting clot structure in 
using this biomarker may therefore be a means of investigating and quantifying the effect of 
chronic inflammation on haemostasis.  As far as we are aware, this technique has not been applied 
to the study of blood clot formation in patients with malignancy.  
 
We hypothesised that blood from lung cancer patients could have modulated mechanical 
properties at its GP compared with healthy controls, given the increased inflammation in these 
patients. In order to test this hypothesis, the present study was designed to investigate whether df 
was significantly different in patients with lung cancer compared to appropriately matched 
controls, and if changes varied with stage of lung cancer. In order to investigate whether high df 
values predict pathological abnormalities in mature clot structure, SEM imaging was also 
performed.  
 
Materials and Methods 
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Patients 
We undertook a prospective, observational study of consecutive patients with histologically or 
cytologically confirmed primary lung cancer diagnosed by the Swansea Multi-Disciplinary Lung 
Cancer Clinic. Exclusion criteria were as follows: 
) Previous history of cancer 
) Active disease known to alter coagulation (e.g. hepatic, renal or haematological  
            disorders) 
) Personal/family history of VTE  
) Anticoagulant therapy  (e.g. warfarin, heparin) 
 
Demographic and clinical information was recorded and anonymised for each patient on initial 
presentation (Table 1). Tumours were staged according to the TNM classification system of the 
American Joint Committee on Cancer (36). Of 105 patients screened, 18 were excluded (14 had a 
history of other malignancy, two samples were not suitable for rheometric analysis, one patient 
had chronic kidney disease and one had a past history of VTE). Patients were sub-divided into 
those with limited disease (stages I or II) and those with extensive disease (stages III or IV). 
Forty-seven age and sex matched healthy volunteers (20 current smokers and 27 non-smokers) 
with no history of cancer or VTE acted as controls. The study was approved by Wales Research 
Ethics Committee 6 (REC Number 07/WMW02/34), and sponsored by Abertawe Bro Morgannwg 
University Health Board Research and Development Office. All subjects gave written, informed 
consent. 
Given the high proportion of patients with smoking history, we undertook a preliminary study to 
compare levels of df in smoking and non-smoking controls. In order to address the effect of co-
morbidities, we compared patients with limited lung cancer (stages I & II) and those with 
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extensive disease (stages III & IV), as the prevalence of co-morbidities appeared similar in both 
groups. A number of patients were on taking therapy for hypertension, hyperlipidaemia and 
prophylactic doses of aspirin (75mg), representative of the population of the study locality. These 
patients were not excluded as it was thought that aspirin therapy would favour the null hypothesis.  
 
Venesection  
Blood was taken from the antecubital vein via a Vacutainer® Needle following diagnosis and 
before any specific therapy was offered. The first 3-5 mls were discarded as waste. Whole venous 
blood was transferred immediately for rheometric analysis. Further samples were transferred into 
vacuum-sealed tubes containing sodium citrate (3.2%) or K2EDTA (Greiner Bio-one, Stonehouse, 
UK) for measurement of standard markers of coagulation and fibrinolysis. 
Rheometric analysis 
The biomarkers (TGP, G`GP & df) which are the focus of this study are obtained from the 
measurement of viscoelastic properties at of the gel point obtained from clotting blood 
(27,29,30,32). A 6.6 ml aliquot of whole unadulterated venous blood was loaded into a double-
gap concentric cylinder measuring geometry of a TA Instruments AR-G2 (TA Instruments, New 
Castle, DE, USA) controlled-stress rheometer (at 37°C ± 0.1ºC) in a near patient setting. All 
rheometric sampling was carried out by members of the research team who were appropriately 
trained and experienced in rheometric analysis. In order to eliminate bias and enhance accuracy of 
measurement, data was anonymised and reviewed independently by three haemorheologists 
blinded to the sample origin, and the mean used for further analysis.  
Computational analysis 
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In order to investigate the relatively small change in df and the previously reported increase in 
fibrin mass of the mature clot (33), computational analysis was carried out. Previously, a 
numerical technique has been used to generate random fractal aggregates where the fractal 
dimension is fixed a priori is presented (37,38). The algorithm utilizes the box-counting measure 
of the fractal dimension to determine the number of hypercubes required to encompass the 
aggregate, on a set of length scales, over which the structure is deemed to be fractal. At each 
length scale the number of required hypercubes are randomly chosen and importantly linked using 
a simple random walk in the embedding dimension. This late step ensures connectivity of the 
random fractal aggregate on all considered length scales. The algorithm is highly efficient and 
overcomes the limitations on the achievable magnitude of the fractal dimension encountered by 
alternative techniques. This provides a visual illustration of clot structure, based on the df values 
measured on whole blood, and allows the corresponding fibrin mass to be calculated.  
Coagulation screen 
Standard time based kinetic markers of clot initiation, propagation and fibrinolysis were carried 
out. PT, APTT and Clauss fibrinogen were measured using a Sysmex CA1500 analyser within 
2 hrs of collection. All reagents were obtained from Siemens, (Frimley, UK). 
 
Thrombin Generation  
Thrombin generation was measured using the Thrombin Generation Assay (TGA, Technoclone 
Diagnostics, Vienna, Austria). 40µL of citrated plasma was dispensed into a 96 well ELISA plate, 
prewarmed to 37ºC (NUNC F16 maxisorp black fluorescence plates, Pathway Diagnostics, 
Dorking, UK). Ten µL of TF was added to a final concentration of 5pM followed by 50µL of 
fluorogenic substrate 1mM Z-G-G-R-AMC (Technoclone Diagnostics, Vienna, Austria). Plates 
were loaded into the fluorogenic plate reader TECAN infinite F200 pro (Labtech International, 
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Uckfield, UK) and read every 60seconds for 1 hour. TGA® software was used to calculate 
individual thrombin generation curves.  
 
Factor VIII Analysis 
Factor VIII was performed as one-stage factor assays on the ACL TOP 500 according to 
manufacturer’s instructions using Instrumentation laboratory calibration plasma, quality control 
material and factor deficient substrate plasma (Instrumentation Laboratory, Warrington, UK).  
 
Fibrinolytic Markers 
PAI-1 antigen was measured using an ELISA assay performed according to manufacturer’s 
instructions (Hyphen Biomed, Quadratech, Epsom, UK). D-Dimer analysis was carried out using 
Latex immunoturbidimetric assay Hemosil HS D-dimer (Instrumentation Laboratory, Warrington, 
UK). The D-dimer assay was performed on an ACL TOP 500 (Instrumentation Laboratory, 
Warrington, UK). 
 
Microparticle assay 
ELISA bio-immunoassay for MP-TF in plasma was performed according to manufacturers 
instructions using calibration and positive and negative controls (Hyphen Biomed, Quadratech, 
Epsom, UK). 
 
Scanning electron microscopy 
SEM samples were prepared by allowing 12µl of whole blood to clot for 15 minutes at 37oC. 
Resulting clots were washed with cacodylate buffer and fixed with gluteraldehyde, before point-
critical dehydration with ethanol (30-100%) and hexamethyldisilazane (Sigma Aldrich, UK). 
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Samples were coated with gold palladium, imaged using a Hitachi Ultra-high resolution FE-SEM 
S-4800, and fibre width of randomly selected regions calculated as previously described (39). 
Statistical analysis 
Power calculations were performed to achieve the primary aim of identifying differences in df 
between a healthy individuals and a pilot group of patients with lung cancer. Parametric data are 
reported as mean (±SD) unless otherwise stated and compared using two-sample t-tests. Pearson 
correlation was undertaken to explore associations between df and standard markers of 
coagulation where significant differences were identified between those with limited compared to 
extensive disease. Statistical analysis was performed using Minitab version 15 software 
(Havertown, PA) and deemed significant when p<0.05.  
Results 
Rheometric Analysis (df) 
Mean df was 1.73±0.04 in healthy individuals and comparable with levels reported in our previous 
study of healthy individuals from the same locality (30).  There was no significant difference in df 
between healthy non-smokers (1.73 ± 0.04) and healthy smokers (1.74 ± 0.03, p=0.10), therefore 
both groups were combined to make a larger group of healthy controls (n= 47).  
Lung cancer patients had a significantly higher df than controls (1.76±0.06 v 1.73±0.04, p<0.05; 
Figure 1a), but there were no significant differences in df between patients with non-small cell and 
small cell lung cancer (1.76 ± 0.06 v 1.78± 0.04, p=0.266). Figure 1b shows that df was also 
significantly increased in patients with extensive disease compared to those with limited disease 
(1.79 ± 0.05 v 1.73 ± 0.05, p<0.05) along with an observed increase in G`GP (0.013 ± 0.006 v 
0.008 ± 0.004, p<0.05). TGP was not significantly different between controls and lung cancer 
patients (231 ± 78 v 216 ± 83s, p=0.243). TGP was higher in patients with extensive disease 
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compared with limited disease (245 ± 107s v 197 ± 63s, Table 2) but the difference failed to reach 
statistical significance (p=0.07). Whilst the study was not powered as a clinical outcome study, it 
is noteworthy that df was significantly increased in patients who died within 12 months of 
diagnosis (1.79 ± 0.06 v 1.74 ± 0.06, p<0.05). 
Computational analysis 
 In patients with lung cancer, relatively small changes in df related to large increases in fibrin 
mass, as calculated by computation analysis. Fibrin mass was on average 150% greater than 
controls and up to 215% in those with extensive disease. In the patient with the highest df, this 
equated to over 700% fibrin mass of healthy controls. Computational models illustrated that 
highly dense clot structures are generated at the highest df values identified in this study, 
compared to those of controls (Figure 2). These images clearly show a significant difference in the 
structures of the clots formed over this range, the high density of red (nodes) in the 1.91 image 
indicates an area of increased cross connectivity, creating a very strong clot, in contrast to that of 
the 1.73 image where there are significantly fewer dense (red) areas.  
Laboratory markers 
All healthy controls were within normal reference ranges (Table 3). No significant differences 
were observed in coagulation screen between controls and patients with lung cancer (PT: 10.4 ± 
0.5s v 10.6 ± 0.6s, p=0.0.784 APTT: 25.8 ± 1.9s v 25.9 ± 1.0s, p=0.845). Nor were there any 
differences between those with limited and extensive disease (PT: 10.6±0.5s v 10.5 ± 0.6s, 
p=0.722; APTT: 26.1 ± 2.8s v 25.7 ± 3.2s, p=0.538). Fibrinogen and platelets were significantly 
higher in patients with lung cancer compared with controls (Fibrinogen 4.2 ± 1.1 v 3.2 ±0.5; 
Platelets: 319 ± 96x109/l v 244 ± 51 x109/l, p<0.05 in both cases), but were not significantly 
higher in extensive compared with limited disease (Fibrinogen: 4.2 ± 1.1g/l v 4.2 ± 1.0g/l, 
p=0.956; Platelets: 326 ± 105 v 310 ± 81, p=0.438).  No statistical differences were identified 
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between patients with limited or extensive disease with regard to markers of coagulation and 
fibrinolysis including thrombin generation, FVIII, MP-TF and D-dimer (Table 4). Conversely, 
PAI-1 was significantly raised in those with extensive compared to those with limited disease 
(10.2±5.9 v 17.6±10.3, p<0.05). No significant differences were observed between those alive at 
12 months and those who had died 12 month from diagnosis (data not shown). 
Correlation analysis 
PAI-1 correlated positively with df in patients with extensive lung cancer (r =0.399, p=0.02), 
suggesting a significant associated between df and this marker of fibrinolytic activity. No 
significant correlation was identified between PAI-1 and df in those with limited disease 
(correlation coefficient=0.245, p=0.248).  
Scanning electron microscopy of mature clot structure 
Clots formed from blood from patients with extensive lung cancer were denser and had a more 
highly branching fibrin network with smaller pore areas than those from patients with limited 
disease or controls (Figure 3). Fibrin fibres were thinner in patients with extensive disease 
(0.16±0.02µM) compared to those with limited disease (0.24±0.06µM) or controls 
(0.27±0.05µM).  
Discussion 
This is the first study to demonstrate differences in microstructural arrangement and mechanical 
properties of blood clots in patients with lung cancer, compared to healthy, age-matched controls, 
as demonstrated by a significantly increased df. Furthermore, significantly increased df values 
were observed in patients with extensive lung cancer compared to those with limited disease 
whilst the two groups appeared evenly matched for confounding variables such as aspirin therapy 
and cardiovascular risk factors. This provides evidence that not only does advanced cancer confer 
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an increased risk of VTE (1-5), but also that pathological clots formed are of abnormally dense 
structure, particularly in those with extensive disease. These findings were also confirmed by 
images generated by SEM, demonstrating clots of highly dense, polymerised structures in patients 
with high df values.  
 
In contrast to rheometric data, we observed no significant differences in standard time-based 
kinetic markers of coagulation between patient groups and controls. These findings were also 
consistent in patients with extensive compared to limited disease.  Whilst patients had 
significantly higher levels of platelets and fibrinogen compared to controls, it is noteworthy that 
all results fell within local normal ranges. Further markers of thrombus initiation (FVIII, TF-
MPs), propagation (TGA) or fibrinolysis (D-dimer), did also not differentiate between patients 
with limited compared to extensive lung cancer. However, results obtained were markedly 
elevated in patients with cancer, particularly those with extensive disease, despite remaining 
within normal ranges. Whilst there was no difference in Factor VIII levels between limited and 
extensive disease, a number of patients had levels near or above the normal range. This is 
consistent with previous publications (7-10), in which patients with malignancies found that 
increased Factor VIII was associated with a 14% cumulative probability of VTE (10), and may 
also be indicative of the chronic inflammation present in these patients. D-dimer has also been 
described to be increased in patients with cancer (40), but our current data suggest that it cannot 
be used to differentiate between local and extensive disease. In contrast to the elevated levels of 
both Factor VIII and D-dimer described, df did differentiate between stages of disease, 
emphasizing its specificity in this population.  
PAI-1 was significantly higher in those with extensive lung cancer, suggesting increased 
suppression of fibrinolytic activity in this group. This is in keeping with previous studies, which 
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have identified increased PAI-1 in various malignancies (41-43), a decrease in fibrinolytic 
efficiency in clots from patients with gastrointestinal cancer (45). Furthermore, PAI-1 
significantly correlate with df in patients with extensive lung cancer, all be it a weak correlation. 
This may suggest that df takes into account suppression of the fibrinolytic system, in combination 
with quantifying the microstructural arrangement of the clot. In our previous study, df was shown 
to be an accurate marker of fibrinolysis and anticoagulation therapy (30,33), and as such may have 
potential to not only quantify thrombogenicity, but also to guide and improve anticoagulation 
therapy. These findings suggest that manipulation of the clot structure may be an effective target 
in therapeutic intervention, given the pathological differences in clot structure observed. 
 
The present study provides additional evidence to support previous studies demonstrating that the 
clot structure, quantified by df, acts as a template predicting the structure of the mature clot 
demonstrated in SEM images. Blood clots from patients with lung cancer who had progressively 
higher levels of df, were found on SEM to be composed of progressively thinner fibrin fibres that 
displayed increased numbers of branching points creating a denser, less porous structure than 
those from healthy individuals. Patients with extensive disease produced clots of the highest 
density with small porous spaces, suggested to be representative of the increased inflammation 
present in those with highest tumour burden, as previously described (12,13). This is consistent 
with previous publications demonstrating that increased df translates to highly polymerised, dense 
clots in patients with inflammatory vascular disease (34,35). These observations are supported by 
the by the significant positive correlation between df and G`GP (p<0.001), the highest values of df 
corresponding to the highest values of clot strength, taking the elastic modulus, G`GP, as 
analogous to that of elasticity or clot ‘strength’.  
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Computational modelling of df values obtained in the study was carried out in order to relate the 
small changes in df to changes in fibrin mass. Increases of fibrin mass of up to 900% were 
calculated in patients with the highest df values, which were also associated with changes in 
microstructural arrangement demonstrate by computational images. These representative images 
confirm that patients with increased df form clots with areas of high cross-connectivity of fibrin 
fibres as illustrated by the increased presence of red (nodal) areas. At df values of 1.73 and 1.79 
there are only a handful of red areas, representing relatively few areas of fibrin cross connectivity. 
At 1.91 the clot is comprised of mainly red nodal areas, representing multiple areas of fibrin 
connectivity, which would translate to clots with highly elastic properties. Consequently these 
clots will mechanically stronger and less susceptible to breakdown. The rheological findings, in 
combination with SEM images and computation analysis, support previous studies identifying 
clots of abnormally dense structure in patients with inflammatory disorders (14,15,19,34,35), 
which may increase resistance of these clots to fibrinolysis (16-18). This supports previous reports 
that not only does chronic inflammation in cancer impact upon tumour progression, but also has 
an effect on systemic process such as haemostasis (11-13), which may have an indirect effect on 
efficiency of the fibrinolytic system.   
 
Our preliminary study comparing df in healthy smokers and non-smokers showed that there was 
no significant difference between the two groups. This is in keeping with a recent epidemiological 
study suggesting that only heavy smoking conveyed an increased VTE risk (46). This suggests 
that the changes in df we observed between lung cancer patients and controls are due to increased 
thrombogenicity of malignancy, and not smoking per se. Furthermore, this study did not find 
significant differences in measures of viscoelasticity or standard measures of coagulation between 
patients with different lung cancer cell types, in contrast to a previous report non-small cell 
tumours are more thrombogenic than small cell tumours (47). 
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There are several advantages to using df in this regard: firstly, it is a rapid and convenient assay on 
unadulterated blood; secondly, it is a global measure of the functional clot properties rather than a 
measure of an individual coagulation component as in conventional coagulation tests. This takes 
into account all aspects of global coagulation, including fibrinolytic activity, assessing all 
functions of the haemostatic system; thirdly, small changes in df represent exponential changes in 
clot mass– physical properties which are likely to influence subsequent clot lysis and potential to 
embolisation.  
 
Whilst our findings indicate the utility of df in assessing clot microstructure in lung cancer 
patients, there are several limitations to this study. Firstly, the numbers of subjects investigated are 
relatively small and our findings will need to be confirmed and validated by larger studies and in 
other malignancies. Secondly, we have not provided prospective information on incidence of 
VTE, which would be required to confirm the utility of df potential biomarker of thrombogenicity 
in clinical practice. In addition, whilst the study was not powered for patient mortality, df was 
significantly increased in patients who died within 12 months of diagnosis. Although this may be 
associated with the increased df in patients with extensive disease, and therefore a poorer 
prognosis, a larger outcome study would provide additional information on whether df is truly 
associated with survival.  
 
In conclusion, this proof of concept study demonstrates that df has the potential to quantify 
differences in pathological clot microstructure in patients with cancer. Furthermore, our biomarker 
may be a means of investigating and quantifying the increasing effects of chronic inflammation 
observed in different stages of lung cancer on global coagulation.  We believe it lays the 
foundation for a paradigm shift away from measuring individual coagulation factors towards the 
measurement of functional activity of pathological clot and its properties. Further studies will be 
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required to investigate the use of df as a marker of clot microstructure and potential 
thrombogenicity in other malignancies, to further validate its reproducibility and define its narrow 
reference range for use in clinical practice. 
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Figures 
 
 
Figure 1: Graph illustrating the changes in df observed in patients with lung cancer 
compared to healthy controls. Graphs illustrating the change in df in A: patients with lung 
cancer (1.76±0.06) compared to healthy controls (1.73±0.04, p<0.05), B: between different 
histopathological tissue types (p>0.05) and C: patients with extensive lung cancer (1.79±0.05) 
compared to patients with limited disease (1.73±0.05, p<0.05). The line represents the mean value 
of the data for each group. * denotes a significant deviation (p<0.05) analysed using a two sample 
t-test. 
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Figure 2: Computational analyses of fibrin mass and clot structure A: Graph illustrating the 
non-linear relationship between the fractal properties of the incipient fibrin clot measured by df 
and the amount of mass, incorporated into the structure. The mass value on the y-axis is 
normalised for the control df =1.73, with the df values of 1.73 (healthy controls and patients with 
limited disease) and 1.79 (patients with extensive disease) annotated. B: Illustrations of fibrin 
mass at values of df = 1.73 (healthy controls and patients with limited disease), 1.79 (patients with 
extensive disease) and 1.91 (highest value obtained in the present study). The colour of each node 
(unit sphere) within the fractal represents the local density of constituent nodes within a sphere of 
radii 5 units, the colour ranges from green (1 neighboring node) to red (20 neighboring nodes). 
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Figure 3: SEM micrographs of mature blood clots. Scanning electron micrographs of mature 
clots in A: Healthy individual, df =1.73, B: patient with stage I lung adenocarcinoma, df =1.74 and 
C: patient with stage IV lung adenocarcinoma, df = 1.78, all at x5.00k magnification using a 
Hitachi Ultra-high resolution FE-SEM S-4800.  Clots were allowed to form at 37°C then imaged 
at room temperature.     
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Table 1: Baseline demographics and tumour information of the lung cancer cohort. (NSCLC 
NOS: Non small cell lung cancer not otherwise specified, TNM: Tumour Nodes Metastases) 
 
 
 
Characteristic Limited Extensive 
n 35 52 
Age  71.7±7.5 69.2±8.0 
Male (%) 16 (46.0) 27 (48.1) 
Non smoker (%) 4 (11.0) 1 (1.9) 
Hypertension (%) 16 (45.7) 17 (32.7) 
Hyperlipidaemia (%) 11 (31.4) 15 (28.8) 
Type 2 Diabetes (%) 4 (11.4) 6 (11.5) 
12 month mortality 6 (17.1) 28 (53.8) 
Aspirin use 9 (25.7) 6 (11.8) 
Histopathological tissue type   
Adenocarcinoma 18 (51.4) 22 (42.3) 
Squamous cell carcinoma 12 (34.3) 15 (28.8) 
Small cell carcinoma 1 (2.9) 13 (25.0) 
NSCLC NOS 4 (11.4) 2 (3.8) 
TNM Classification   
Stage 1 23 (65.7) - 
Stage 2 12 (34.3) - 
Stage 3 - 30 (57.7) 
Stage 4 - 22 (42.3) 
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Table 2: Rheometric data for patients with lung cancer and healthy controls. Rheometric 
data (df: fractal dimension, TGP: Gel time) as measured in the lung cancer cohort compared to 
healthy controls, and analysed based on tissue type and stage of disease.  
 
 
 
 
 df p-value TGP (secs) p-value 
Healthy controls 1.73 ± 0.04 <0.05 231 ± 78 0.243 
(Range) (1.63-1.79)  (90-369)  
Lung cancer 1.76 ± 0.06  216 ± 83  
(Range) (1.64-1.91)  (80-366)  
     
Non-small cell lung cancer 1.76 ± 0.06 0.266 209 ± 84 0.552 
(Range) (1.64-1.91)  (80-344)  
Small cell lung cancer 1.78 ± 0.04  228 ± 84  
(Range) (1.72-1.82)  (136-366)  
     
Limited (Stages 1&2) 1.73 ± 0.05 <0.05 245 ± 107 0.072 
(Range) (1.64-1.81)  (113-344)  
Extensive (Stages 3&4) 1.79 ± 0.05  197 ± 63  
(Range) (1.71-1.91)  (80-366)  
     
Alive at 12 months 1.74±0.06 <0.05   
RIP at 12 months 1.79±0.06    
! 28!
! PT#(sec)# p*value# APTT#(sec)# p*value# Clauss#
fibrinogen#
(g/l)#
p*value# Platelets#
(x10#^9)#
p*value#
Healthy# 10.4!±!0.5! 0.784! 25.8!±!1.9! 0.845! 3.2!±!0.5! <0.05! 244±51! <0.05!
Lung#Cancer# 10.6!±!0.6! ! 25.9!±!1.0! ! 4.2!±!1.1! ! 319!±!96! !
# ! ! ! ! ! ! ! !
Limited#
(stages#1&#2)#
10.6!±!0.5! 0.722! 26.1!±!2.8! 0.538! 4.2!±!1.0! 0.956! 310!±!81! 0.438!
Extensive#
(stages#3&4)#
10.5!±!0.6! ! 25.7!±!3.2! ! 4.2!±!1.1! ! 326!±!105! !
 
Table 3: Conventional markers of coagulation as measured in healthy controls compared to 
lung cancer patients and patients with limited disease (stages 1&2) compared to extensive 
disease (stages 3&4).  (PT: Prothrombin time; APTT: Activated partial thromboplastin time) 
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Table 4: Additional measures of haemostasis in patients with limited (stages 1&2) compared 
to extensive (stages 3&4) lung cancer. (FVIII: Factor VIII; TF MP: Tissue Factor 
Microparticles; PAI-1: Plasminogen activator inhibitor-1) 
 Limited 
(Stages 1&2) 
Extensive 
 (Stages 3&4) 
p-value Normal 
range 
Thrombin generation 
(nM) 
400 ±133 425 ±138 0.489 140-440 
FVIII (IU/L) 131.3 ± 39.7 143.3 ± 48.4 0.311 50-150 
TF MP 0.417 ± 0.381 0.594 ± 0.401 0.096 <2.0 
 
Fibrinolytic markers 
    
PAI-1 10.2 ± 5.9 17.6 ± 10.3 <0.005 <25.0 
D-dimer 280 ± 162 461 ± 670 0.096 <240 
